{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:07:37Z","timestamp":1788955657526,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intra-detrusor injection of botulinum neurotoxin type A (BoNT\/A) is recommended as a possible treatment for patients with overactive bladder (OAB) in whom first-line therapies have failed. The c.190T\u2009&gt;\u2009C (rs4994) polymorphism in the gene encoding the beta-3 adrenergic receptor (<jats:italic>ADRB3<\/jats:italic>) has been suggested to be associated with predisposition to OAB or with response to OAB treatment via a cholinergic muscarinic receptor antagonist. This prospective study aimed to use a urodynamic parameter-based assessment of response, six months after a single intra-detrusor injection of BoNT\/A in female OAB patients, to elucidate possible association with the <jats:italic>ADRB3<\/jats:italic> polymorphism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study group consisted of 138 consecutive, Polish, adult, female OAB patients. Urodynamic parameters were recorded before injection of BoNT\/A and at six months after administration. <jats:italic>ADRB3<\/jats:italic>:rs4994 variants were identified by the sequencing of genomic DNA extracted from buccal swabs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Apart from baseline, and relative, increase in Maximum Cystometric Capacity (MCC) six months after BoNT\/A injection, no significant differences were found in urodynamic parameters between reference TT homozygotes and women with at least one C allele.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results do not exclude that <jats:italic>ADRB3<\/jats:italic>:rs4994 variants are associated with a positive urodynamic test-based response to intra-detrusor injection of BoNT\/A in females with OAB.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s43440-024-00647-9","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T06:02:27Z","timestamp":1726034547000},"page":"1489-1500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association analysis of ADRB3:rs4994 with urodynamic outcome, six months after a single intra-detrusor injection of botulinum toxin, in women with overactive bladder"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9586-5810","authenticated-orcid":false,"given":"Sylwester","family":"Cie\u0107wie\u017c","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-2341","authenticated-orcid":false,"given":"Klaudyna","family":"Lewandowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-5329","authenticated-orcid":false,"given":"Aleksandra","family":"Szyli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-5726","authenticated-orcid":false,"given":"Agnieszka","family":"Boro\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-9656","authenticated-orcid":false,"given":"Dariusz","family":"Kotl\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-9333","authenticated-orcid":false,"given":"Jacek","family":"Kociszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-1648","authenticated-orcid":false,"given":"Agnieszka","family":"Brodowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-5638","authenticated-orcid":false,"given":"Jeremy S.C.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-440X","authenticated-orcid":false,"given":"Andrzej","family":"Ciechanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"647_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00345-011-0742-8","volume":"30","author":"P Abrams","year":"2012","unstructured":"Abrams P, Chapple CR, J\u00fcnemann KP, Sharpe S. Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. World J Urol. 2012;30:385\u201392. https:\/\/doi.org\/10.1007\/s00345-011-0742-8.","journal-title":"World J Urol"},{"key":"647_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00192-014-2362-5","volume":"25","author":"BT Haylen","year":"2014","unstructured":"Haylen BT, Chiu TL, Avery D, Zhou J, Law M. Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone. Int Urogynecol J. 2014;25:1115\u201320. https:\/\/doi.org\/10.1007\/s00192-014-2362-5.","journal-title":"Int Urogynecol J"},{"key":"647_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/DNND.S40349","volume":"4","author":"KD Ethans","year":"2014","unstructured":"Ethans KD, Casey AR, Bard RJ, Namaka MP. Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxin A. Degener. Neurol Neuromuscul Dis. 2014;4:65\u201375. https:\/\/doi.org\/10.2147\/DNND.S40349.","journal-title":"Neurol Neuromuscul Dis"},{"key":"647_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11884-023-00690-x","volume":"18","author":"R Chess-Williams","year":"2023","unstructured":"Chess-Williams R, Sellers DJ. Pathophysiological mechanisms involved in overactive Bladder\/Detrusor overactivity. Curr Bladder Dysfunct Rep. 2023;18:79\u201388. https:\/\/doi.org\/10.1007\/s11884-023-00690-x.","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"647_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.12669\/pjms.37.4.4262","volume":"37","author":"S Rashid","year":"2021","unstructured":"Rashid S, Babur MN, Khan RR, Khalid MU, Mansha H, Riaz S. Prevalence and associated risk factors among patients with overactive bladder syndrome in Pakistan. Pak J Med Sci. 2021;37:1185\u20139. https:\/\/doi.org\/10.12669\/pjms.37.4.4262.","journal-title":"Pak J Med Sci"},{"key":"647_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4081\/aiua.2022.1.46","volume":"94","author":"B Barone","year":"2022","unstructured":"Barone B, De Luca L, Napolitano L, Reccia P, Crocetto F, Creta M, et al. Lower urinary tract symptoms and mental health during COVID-19 pandemic. Arch Ital Urol Androl. 2022;94:46\u201350. https:\/\/doi.org\/10.4081\/aiua.2022.1.46.","journal-title":"Arch Ital Urol Androl"},{"key":"647_CR7","doi-asserted-by":"publisher","unstructured":"Hannestad YS, Lie RT, Rortveit G, Hunskaar S. Familial risk of urinary incontinence in women: Population based cross sectional study. BMJ. 2004;329:889\u2013891. https:\/\/doi.org\/10.1136\/bmj3297471889","DOI":"10.1136\/bmj3297471889"},{"key":"647_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j0001-6349200400635x","volume":"83","author":"G Rohr","year":"2004","unstructured":"Rohr G, Kragstrup J, Gaist D, Christensen K. Genetic and environmental influences on urinary incontinence: a Danish population-based twin study of middle-aged and elderly women. Acta Obs Gynecol Scand. 2004;83:978\u201382. https:\/\/doi.org\/10.1111\/j0001-6349200400635x","journal-title":"Acta Obs Gynecol Scand"},{"key":"647_CR9","doi-asserted-by":"publisher","unstructured":"Wennberg AL, Altman D, Lundholm C, Klint A, Iliadou A, Peeker R et al. Genetic influences are important for most but not all lower urinary tract symptoms: a population-based survey in a cohort of adult Swedish twins. Eur. Urol. 2011;59:1032\u20131038. https:\/\/doi.org\/10.1016\/jeururo201103007","DOI":"10.1016\/jeururo201103007"},{"key":"647_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.juro.2014.12.023","volume":"193","author":"HE Richter","year":"2015","unstructured":"Richter HE, Whitehead N, Arya L, Ridgeway B, Allen-Brady K, Norton P, et al. Genetic contributions to urgency urinary incontinence in women. J Urol. 2015;193:2020\u20137.","journal-title":"J Urol"},{"key":"647_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/JU0000000000000655","volume":"203","author":"KL Penney","year":"2020","unstructured":"Penney KL, Townsend MK, Turman C, Glass K, Staller K, Kraft P, et al. Genome-Wide Association Study for Urinary and Fecal Incontinence in Women. J Urol. 2020;203:978\u201383. https:\/\/doi.org\/10.1097\/JU0000000000000655","journal-title":"J Urol"},{"key":"647_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/JU0000000000001822","volume":"206","author":"R Cartwright","year":"2021","unstructured":"Cartwright R, Franklin L, Tikkinen KAO, Kalliala I, Miotla P, Rechberger T, et al. A Genome-Wide Association Study Identifies Two Novel Loci Associated with Female Stress and Urgency Urinary Incontinence. J Urol. 2021;206:679\u201387. https:\/\/doi.org\/10.1097\/JU0000000000001822","journal-title":"J Urol"},{"key":"647_CR13","doi-asserted-by":"publisher","unstructured":"Pi\u0119tak P PA, Rechberger T. Overactive bladder as a dysfunction of the autonomic nervous system\u2013 a narrative review. Eur J Obs Gynecol Reprod Biol. 2022;271:102\u20137. https:\/\/doi.org\/10.1016\/jejogrb202201022","DOI":"10.1016\/jejogrb202201022"},{"key":"647_CR14","doi-asserted-by":"publisher","unstructured":"Igawa Y, Aizawa N, Michel MC. \u03b23-Adrenoceptors in the normal and diseased urinary bladder-What are the open questions? Br. J. Pharmacol. 2019; 176:2525\u20132538. https:\/\/doi.org\/10.1111\/bph14658","DOI":"10.1111\/bph14658"},{"key":"647_CR15","doi-asserted-by":"publisher","first-page":"930084","DOI":"10.3389\/fgene2022930084","volume":"13","author":"R Dai","year":"2022","unstructured":"Dai R, Chen Y, Yang K, Wu T, Deng C. Association Between Trp64Arg Polymorphism of Beta-3 Adrenergic Receptor Gene and Susceptibility to Overactive Bladder: a Meta-analysis. Front Genet. 2022;13:930084. https:\/\/doi.org\/10.3389\/fgene2022930084","journal-title":"Front Genet"},{"key":"647_CR16","doi-asserted-by":"publisher","unstructured":"Ferreira CE, Fonseca AM, Silva ID, Gir\u00e3o MJ, Sartori MG, Castro RA. The relationship between the Trp 64 Arg polymorphism of the beta 3-adrenoceptor gene and idiopathic overactive bladder. Am. J. Obs. Gynecol. 2011;205:e10\u2013e14. https:\/\/doi.org\/10.1016\/jajog201102052","DOI":"10.1016\/jajog201102052"},{"key":"647_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/nau22476","volume":"33","author":"K Honda","year":"2014","unstructured":"Honda K, Yamaguchi O, Nomiya M, Shishido K, Ishibashi K, Takahashi N, et al. Association between polymorphism of beta3-adrenoceptor gene and overactive bladder. Neurourol Urodyn. 2014;33:400\u20132. https:\/\/doi.org\/10.1002\/nau22476","journal-title":"Neurourol Urodyn"},{"key":"647_CR18","doi-asserted-by":"publisher","unstructured":"Pi\u00e9tri-Rouxel F, St John Manning B, Gros J, Strosberg AD. The biochemical effect of the naturally occurring Trp64\u2013>Arg mutation on human beta3-adrenoceptor activity. Eur. J. Biochem. 1997;247:1174\u20131179. https:\/\/doi.org\/10.1111\/j1432-1033199701174x","DOI":"10.1111\/j1432-1033199701174x"},{"key":"647_CR19","doi-asserted-by":"publisher","unstructured":"Cartwright R, Kirby AC, Tikkinen KA, Mangera A, Thiagamoorthy G, Rajan P et al. Systematic review and metaanalysis of genetic association studies of urinary symptoms and prolapse in women. Am. J. Obstet. Gynecol. 2015;212:199.e1-24. https:\/\/doi.org\/10.1016\/jajog201408005","DOI":"10.1016\/jajog201408005"},{"key":"647_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/nau25082","volume":"42","author":"MC Michel","year":"2023","unstructured":"Michel MC. Are \u03b23 -adrenoceptor gene polymorphisms relevant for urology? Neurourol. Urodyn. 2023;42:33\u20139. https:\/\/doi.org\/10.1002\/nau25082","journal-title":"Urodyn"},{"key":"647_CR21","doi-asserted-by":"publisher","unstructured":"\u00c7irako\u011flu A, Fejzullahu A, Benli E, Yuce A, Ayy\u0131ld\u0131z A, Aynac\u0131o\u011flu A\u015e. Association between the Trp64Arg polymorphism of the ADRB3 gene and overactive bladder. Neurourol. Urodyn. 2021;40:1780\u20131785. https:\/\/doi.org\/10.1002\/nau24742","DOI":"10.1002\/nau24742"},{"key":"647_CR22","doi-asserted-by":"publisher","unstructured":"Firat E, Aybek Z, Akg\u00fcn \u015e, K\u00fc\u00e7\u00fcker K, Ak\u00e7a H, Aybek H. Relation of ADRB3, GEF, ROCK2 gene polymorphisms to clinical findings in overactive bladder. World J. Urol. 2020;38:2571\u20132575. https:\/\/doi.org\/10.1007\/s00345-019-03046-5","DOI":"10.1007\/s00345-019-03046-5"},{"key":"647_CR23","doi-asserted-by":"publisher","unstructured":"Gurocak S, Konac E, Ure I, Senol C, Onen IH, Sozen S, et al. A the impact of gene polymorphisms on the success of anticholinergic treatment in children with overactive bladder. Dis Markers. 2015;2015(732686). https:\/\/doi.org\/10.1155\/2015\/732686","DOI":"10.1155\/2015\/732686"},{"key":"647_CR24","doi-asserted-by":"publisher","unstructured":"Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur. Urol. 2006;49:519\u2013527. https:\/\/doi.org\/10.1016\/jeururo200511006","DOI":"10.1016\/jeururo200511006"},{"key":"647_CR25","doi-asserted-by":"publisher","unstructured":"Dan Spinu A, Gabriel Bratu O, Cristina Diaconu C, Maria Alexandra Stanescu A, Bungau S, Fratila O et al. Botulinum toxin in low urinary tract disorders - Over 30 years of practice (Review). Exp. Med. 2020;20:117\u2013120. https:\/\/doi.org\/10.3892\/etm20208664","DOI":"10.3892\/etm20208664"},{"key":"647_CR26","doi-asserted-by":"publisher","unstructured":"Abrar M, Pindoria N, Malde S, Chancellor M, DeRidder D, Sahai A. Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. Eur. Urol. Focus. 2021;7:1448\u20131467. https:\/\/doi.org\/10.1016\/jeuf202006013","DOI":"10.1016\/jeuf202006013"},{"key":"647_CR27","doi-asserted-by":"publisher","unstructured":"Cie\u0107wie\u017c SM, Lewandowska K, Boro\u0144 A, Brodowski J, Kociszewski J, Clark JS, et al. A functional polymorphism in the ADRB3 gene, encoding the Beta-3 adrenergic receptor, and response to Intra-detrusor Injection of Botulinum Toxin-A in Women with overactive bladder. J Clin Med. 2022;11:7491. https:\/\/doi.org\/10.3390\/jcm11247491","DOI":"10.3390\/jcm11247491"},{"key":"647_CR28","doi-asserted-by":"publisher","unstructured":"Sahai A, Khan MS, Le Gall N, Dasgupta P, GKT Botulinum Study Group. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology,. 2008;71:455\u2013459. https:\/\/doi.org\/10.1016\/jurology200711039","DOI":"10.1016\/jurology200711039"},{"key":"647_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","volume":"176","author":"DM Schmid","year":"2006","unstructured":"Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177\u201385.","journal-title":"J Urol"},{"key":"647_CR30","doi-asserted-by":"publisher","unstructured":"Cie\u0107wie\u017c S, Che\u0142stowski K, Brodowska A, Ptak M, Kotl\u0119ga D, Starczewski A. Association between the Urinary Bladder Volume and the Incidence of De Novo Overactive Bladder in Patients with Stress Urinary Incontinence Subjected to Sling Surgeries or Burch Procedure. Biomed. Res. Int. 2019;2019:9515242. https:\/\/doi.org\/10.1155\/2019\/9515242","DOI":"10.1155\/2019\/9515242"},{"key":"647_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/nau.23124","volume":"36","author":"PFWM Rosier","year":"2017","unstructured":"Rosier PFWM, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, et al. International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36:1243\u201360. https:\/\/doi.org\/10.1002\/nau.23124","journal-title":"Neurourol Urodyn"},{"issue":"S6","key":"647_CR32","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/nau.23768","volume":"37","author":"MJ Drake","year":"2018","unstructured":"Drake MJ. Fundamentals of terminology in lower urinary tract function. Neurourol Urodyn. 2018;37(S6):S13\u20139. https:\/\/doi.org\/10.1002\/nau.23768.","journal-title":"Neurourol Urodyn"},{"key":"647_CR33","unstructured":"Yao M, Simoes A. Urodynamic Testing and Interpretation. [Updated 2023 Aug 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562310\/"},{"key":"647_CR34","doi-asserted-by":"publisher","unstructured":"Carle S, Pirazzini M, Rossetto O, Barth H, Montecucco C. High conservation of Tetanus and Botulinum neurotoxins cleavage sites on Human SNARE proteins suggests that these pathogens exerted little or no evolutionary pressure on humans. Toxins. 2017;9(404). https:\/\/doi.org\/10.3390\/toxins9120404","DOI":"10.3390\/toxins9120404"},{"key":"647_CR35","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00204-022-03271-9","volume":"96","author":"M Pirazzini","year":"2022","unstructured":"Pirazzini M, Montecucco C, Rossetto O. Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update. Arch Toxicol. 2022;96:1521\u201339. https:\/\/doi.org\/10.1007\/s00204-022-03271-9","journal-title":"Arch Toxicol"},{"key":"647_CR36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/acn3586","volume":"5","author":"M Pirazzini","year":"2018","unstructured":"Pirazzini M, Carle S, Barth H, Rossetto O, Montecucco C. Primary resistance of human patients to botulinum neurotoxins a and B. Ann Clin Transl Neurol. 2018;5:971\u20135. https:\/\/doi.org\/10.1002\/acn3586","journal-title":"Ann Clin Transl Neurol"},{"key":"647_CR37","doi-asserted-by":"publisher","unstructured":"Moreno-Mayordomo R, Ruiz M, Pascual J, Gallego de la Sacristana M, Vidriales I, Sobrado M, et al. CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain. 2019;20(39). https:\/\/doi.org\/10.1186\/s10194-019-0989-9","DOI":"10.1186\/s10194-019-0989-9"},{"key":"647_CR38","doi-asserted-by":"publisher","unstructured":"Chohan N, Hilton P, Brown K, Dixon L. Efficacy and duration of response to botulinum neurotoxin A (onabotulinum A) as a treatment for detrusor overactivity in women. Int. Urogynecol. J. 2015;26:1605\u20131612. https:\/\/doi.org\/10.1007\/s00192-015-2751-4","DOI":"10.1007\/s00192-015-2751-4"},{"key":"647_CR39","doi-asserted-by":"publisher","unstructured":"Kennelly M, Cruz F, Herschorn S, Abrams P, Onem K, Solomonov VK et al. Efficacy and Safety of Abobotulinumtoxin A in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2). Eur. Urol. 2022;82:223\u2013232. https:\/\/doi.org\/10.1016\/jeururo202203010","DOI":"10.1016\/jeururo202203010"},{"issue":"S1","key":"647_CR40","doi-asserted-by":"publisher","first-page":"e32377","DOI":"10.1097\/MD.0000000000032377","volume":"102","author":"V Nitti","year":"2023","unstructured":"Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): development, insights, and impact. Med (Baltim). 2023;102(S1):e32377. https:\/\/doi.org\/10.1097\/MD.0000000000032377.","journal-title":"Med (Baltim)"},{"key":"647_CR41","doi-asserted-by":"publisher","unstructured":"Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 2007;177:2231\u20132236. https:\/\/doi.org\/10.1016\/jjuro200701130","DOI":"10.1016\/jjuro200701130"},{"key":"647_CR42","doi-asserted-by":"publisher","unstructured":"Ghalayini IF, Al-Ghazo MA. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol. Urodyn. 2007;26:531\u2013536. https:\/\/doi.org\/10.1002\/nau20403","DOI":"10.1002\/nau20403"},{"key":"647_CR43","doi-asserted-by":"publisher","unstructured":"Lwow F, Dunajska K, Milewicz A, Laczma\u0144ski L, Jedrzejuk D, Trzmiel-Bira A. ADRB3 and PPAR\u03b32 gene polymorphisms and their association with cardiovascular disease risk in postmenopausal women. Climacteric. 2013;16:473\u2013478. https:\/\/doi.org\/10.3109\/136971372012738721","DOI":"10.3109\/136971372012738721"},{"key":"647_CR44","doi-asserted-by":"publisher","unstructured":"Grygiel-G\u00f3rniak B, Kaczmarek E, Mosor M, Przys\u0142awski J, Nowak J. Gene-diet-related factors of hyperglycaemia in postmenopausal women. J. Appl. Genet. 2018;59:169\u2013177. https:\/\/doi.org\/10.1007\/s13353-018-0434-9","DOI":"10.1007\/s13353-018-0434-9"},{"key":"647_CR45","doi-asserted-by":"publisher","unstructured":"Grygiel-G\u00f3rniak B, Zi\u00f3\u0142kowska-Suchanek I, Kaczmarek E, Puszczewicz M, Rozwadowska N. Genetic Background of Hypertension in Connective Tissue Diseases. J. Immunol. Res. 2020;2020:7509608. https:\/\/doi.org\/10.1155\/2020\/7509608","DOI":"10.1155\/2020\/7509608"},{"key":"647_CR46","doi-asserted-by":"publisher","unstructured":"Dunajska K, Lwow F, Milewicz A, Jedrzejuk D, Laczmanski L, Belowska-Bien K et al. A beta(3)-adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women. Gynecol. Endocrinol. 2008;24:133\u2013138. https:\/\/doi.org\/10.1080\/09513590801921686","DOI":"10.1080\/09513590801921686"},{"key":"647_CR47","doi-asserted-by":"publisher","unstructured":"Meekins AR, Murphy SK, Grenier C, Huang Z, Bradley MS, Amundsen CL et al. Role of \u03b2-3 adrenergic receptor polymorphism in overactive bladder. Neurour. Urodyn. 2019;38: 1261\u20131265. https:\/\/doi.org\/10.1002\/nau24006","DOI":"10.1002\/nau24006"},{"key":"647_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1375\/twin.11.3.249","volume":"11","author":"O Mayo","year":"2008","unstructured":"Mayo O. A century of Hardy-Weinberg equilibrium. Twin Res Hum Genet. 2008;11:249\u201356. https:\/\/doi.org\/10.1375\/twin.11.3.249","journal-title":"Twin Res Hum Genet"},{"key":"647_CR49","first-page":"65","volume":"3","author":"C Andrews","year":"2010","unstructured":"Andrews C. The Hardy-Weinberg Principle. Nat Educ Knowl. 2010;3:65.","journal-title":"Nat Educ Knowl"},{"key":"647_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.22074\/cellj.2016.3711","volume":"17","author":"A Namipashaki","year":"2015","unstructured":"Namipashaki A, Razaghi-Moghadam Z, Ansari-Pour N. The Essentiality of Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based Genetic Association Studies. Cell J. 2015;17:187\u201392. https:\/\/doi.org\/10.22074\/cellj.2016.3711","journal-title":"Cell J"},{"key":"647_CR51","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.euf.2020.01.005","volume":"6","author":"E Finazzi Agr\u00f2","year":"2020","unstructured":"Finazzi Agr\u00f2 E, Bianchi D, Iacovelli V. Pitfalls in Urodynamics. Eur Urol Focus. 2020;6:820\u20132. https:\/\/doi.org\/10.1016\/j.euf.2020.01.005.","journal-title":"Eur Urol Focus"},{"key":"647_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12920-022-01216-w","volume":"15","author":"AJ Alsheikh","year":"2022","unstructured":"Alsheikh AJ, Wollenhaupt S, King EA, Reeb J, Ghosh S, Stolzenburg LR, et al. The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases. BMC Med Genomics. 2022;15:74. https:\/\/doi.org\/10.1186\/s12920-022-01216-w.","journal-title":"BMC Med Genomics"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00647-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00647-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00647-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:19:41Z","timestamp":1732169981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00647-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["647"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00647-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}